Anticoagulantes orales directos: monitorización y reversión, dos grandes dificultades

La tromboembolia representa una importante causa de morbimortalidad, siendo la anticoagulación el pilar del tratamiento. Los anticoagulantes orales directos, constituyen una opción que supera algunos de los inconvenientes con warfarina, como la monitorización rutinaria. No obstante con su inclusión...

Full description

Autores:
Carrillo Navarro, María Claudia
Guerrero García, Augusto Santiago
Tipo de recurso:
Trabajo de grado de pregrado
Fecha de publicación:
2016
Institución:
Universidad Libre
Repositorio:
RIU - Repositorio Institucional UniLibre
Idioma:
spa
OAI Identifier:
oai:repository.unilibre.edu.co:10901/10236
Acceso en línea:
https://hdl.handle.net/10901/10236
Palabra clave:
Anticoagulantes
Tromboembolia
Tromboembolia
Tromboembolia
Medicamentos
Dabigatran
Rivaroxaban
Apixaban
Monitoring
Bleeding
HEMORRAGIA
DABIGATRÁN
RIVAROXABÁN
APIXABÁN
Dabigatrán
Rivaroxabán
Apixabán
Monitorización
Sangrado
Rights
openAccess
License
http://creativecommons.org/licenses/by-nc-nd/2.5/co/
id RULIBRE2_1cfe33ca9a667a82be6293066eb61005
oai_identifier_str oai:repository.unilibre.edu.co:10901/10236
network_acronym_str RULIBRE2
network_name_str RIU - Repositorio Institucional UniLibre
repository_id_str
dc.title.spa.fl_str_mv Anticoagulantes orales directos: monitorización y reversión, dos grandes dificultades
title Anticoagulantes orales directos: monitorización y reversión, dos grandes dificultades
spellingShingle Anticoagulantes orales directos: monitorización y reversión, dos grandes dificultades
Anticoagulantes
Tromboembolia
Tromboembolia
Tromboembolia
Medicamentos
Dabigatran
Rivaroxaban
Apixaban
Monitoring
Bleeding
HEMORRAGIA
DABIGATRÁN
RIVAROXABÁN
APIXABÁN
Dabigatrán
Rivaroxabán
Apixabán
Monitorización
Sangrado
title_short Anticoagulantes orales directos: monitorización y reversión, dos grandes dificultades
title_full Anticoagulantes orales directos: monitorización y reversión, dos grandes dificultades
title_fullStr Anticoagulantes orales directos: monitorización y reversión, dos grandes dificultades
title_full_unstemmed Anticoagulantes orales directos: monitorización y reversión, dos grandes dificultades
title_sort Anticoagulantes orales directos: monitorización y reversión, dos grandes dificultades
dc.creator.fl_str_mv Carrillo Navarro, María Claudia
Guerrero García, Augusto Santiago
dc.contributor.advisor.none.fl_str_mv González Aguirre, Irene
Iglesias Acosta, Jesús
dc.contributor.author.none.fl_str_mv Carrillo Navarro, María Claudia
Guerrero García, Augusto Santiago
dc.subject.spa.fl_str_mv Anticoagulantes
Tromboembolia
Tromboembolia
Tromboembolia
Medicamentos
topic Anticoagulantes
Tromboembolia
Tromboembolia
Tromboembolia
Medicamentos
Dabigatran
Rivaroxaban
Apixaban
Monitoring
Bleeding
HEMORRAGIA
DABIGATRÁN
RIVAROXABÁN
APIXABÁN
Dabigatrán
Rivaroxabán
Apixabán
Monitorización
Sangrado
dc.subject.subjectenglish.eng.fl_str_mv Dabigatran
Rivaroxaban
Apixaban
Monitoring
Bleeding
dc.subject.lemb.spa.fl_str_mv HEMORRAGIA
DABIGATRÁN
RIVAROXABÁN
APIXABÁN
dc.subject.proposal.spa.fl_str_mv Dabigatrán
Rivaroxabán
Apixabán
Monitorización
Sangrado
description La tromboembolia representa una importante causa de morbimortalidad, siendo la anticoagulación el pilar del tratamiento. Los anticoagulantes orales directos, constituyen una opción que supera algunos de los inconvenientes con warfarina, como la monitorización rutinaria. No obstante con su inclusión en la práctica clínica, surgieron otras limitaciones: la dificultad para su medición cuando se requiere, debido a la poca disponibilidad y estandarización de pruebas hemostáticas; y la falta de antídotos para reversión, frente a hemorrágicas severas. Sin embargo recientemente fue aprobado idarucizumab, un anticuerpo monoclonal que neutraliza al dabigatrán, no disponible en Colombia. Se concluye que estos fármacos, son una opción atractiva, que requieren el desarrollo de pruebas diagnósticas y agentes de reversión específicos accesibles. Se realizó una búsqueda en bases de datos como Pubmed, Clinical Key, Embase, Evidence- Based MEDICINE, con las palabras clave dabigatrán, rivaroxabán, apixabán, monitorización, sangrado. Se incluyó literatura en idioma inglés y español entre 1998-2016.
publishDate 2016
dc.date.created.none.fl_str_mv 2016
dc.date.accessioned.none.fl_str_mv 2017-07-26T19:02:54Z
dc.date.available.none.fl_str_mv 2017-07-26T19:02:54Z
dc.type.local.spa.fl_str_mv Tesis de Especialización
dc.type.hasversion.spa.fl_str_mv info:eu-repo/semantics/acceptedVersion
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_7a1f
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/bachelorThesis
format http://purl.org/coar/resource_type/c_7a1f
status_str acceptedVersion
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/10901/10236
dc.identifier.instname.spa.fl_str_mv instname:Universidad Libre
dc.identifier.reponame.spa.fl_str_mv reponame:Repositorio Institucional Universidad Libre
url https://hdl.handle.net/10901/10236
identifier_str_mv instname:Universidad Libre
reponame:Repositorio Institucional Universidad Libre
dc.language.iso.none.fl_str_mv spa
language spa
dc.relation.references.eng.fl_str_mv Mozaffarian D, Roger Vl, Benjamin BJ, Berry JD, Blaha MJ, et. al. Heart disease and stroke. Statistics—2014 Update A Report From The American Heart Association. Circulation. 2014; (129): 399-410.
Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna Wp, et al. Secular trends in incidence of atrial fibrillation in olmsted county, minnesota, 1980 To 2000, And Implications On The Projections For Future Prevalence. Circulation. 2006; 114:119–25
Ezekowitz MD, Falk RH. The increasing need for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Mayo Clin Proc. 2004: 79:904–13.
Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet.1998; 352:1167–71.
Hart R, Diener H, Shelagh B, Coutts MD,Donald Easton J, Granger C, O'donnell M, et al. Embolic strokes of undetermined source: The case for a new clinical construc. The Lancet Neurology. 2014; (13): 429-438.
Kernan WN, Chair MD, Ovbiagele B, Chair V, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack a guideline for healthcare professionals from the American heart association/american stroke association. Stroke. 2014. (45):1-77.
Bhupathiraju SN, Hu FB, et al. Epidemiology of obesity and diabetes and their cardiovascular complications. Circ Res. 2016; 118(11):1723-35.
Marín F, Sánchez P, Cortina JM, García JA, Jiménez D, Lecumberri R, et al. Comentarios a la guía de práctica clínica de la ESC 2014 sobre el diagnóstico y tratamiento de la embolia pulmonar aguda Rev Esp Crdaridoilo. 2015; 68 (1): 10- 16.
Paul D, Stein Md Y Fadi Matta Md. Epidemiology and Incidence: The scope of the problem and risk factors for development of venous thromboembolism. Crit Care Clin Volumen 2011; 907–932
Stein PD, Matta F. Acute pulmonary embolism. Curr Prob Cardiol 2010; 35:314–76.
Ubaldini J, Chertcoff J, Sampó E, Casey M, Ceresetto J, Boughen R. Consenso de enfermedad tromboembólica- consenso argentino sac. Revista Argentina De Cardiología. 2009; 77(5): 411-428.
Dennis R, Rojas MX, Molina A, Roa J, Granados M, Londoño A, et al. Clinical course and survival in pulmonary embolism results of the Colombian multicentric registry (emepco). Acta Médica Colombiana. 2008 Volumen (33 N° 3): 111-116.
January C, Wann S, Alpert J, Field M, Calkins H, Murray K, et al. Aha/Acc/Hrs guideline for the management of patients withatrial fibrillationa report of the american college of cardiology/american heart association task force on practice guidelines and the heart rhythm society. Circulation. 2014; (129:000–000)
Hart R, Lesly A. Pearce, et al. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146(12):857-867.
Fernández M, Rueda Y, Villa V, Belmonte S, Stoyanova A. Análisis del perfil sociosanitario del paciente anticoagulado en España. Federación Española De Asociaciones De Anticoagulados. 2013.
Brummel K, Kenneth G. Molecular basis of blood coagulation. En: Hoffman, Ronald. Hematology: Basic Principles and Practice, Sixth Edition. New York USA. Elsevier. 2013; 1821-1841.
Kang-Ling W, Pao-Hsien C, Cheng-Han L, Pei-Ying P, Pao-Yen L, Kou-Gi S, et al. Management Of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis. Act Cardiol Sin. 2016; 32:122.
Aguilar M, Hart R, Pearce L. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patientswith non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007; (6): 186- 198
Fontana P, Robert-Ebadi H, Bounameaux H, Boehlen F, Righini M. Direct oral anticoagulants: A Guide For Daily Practice. Medical Intelligence. 2016; 146:W14286.
Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors of thrombin and factor Xa: A recommendation from the subcommittee on control of anticoagulation of the scientific and standardization committee of the international society on thrombosis and haemostasis. J Thromb Haemost 2013; 11: 756–60.
Fontana P, Goldhaber S, Bounameaux H. Anticoagulantes orales directas en el tratamiento y la prevención a largo plazo del tromboembolismo venoso. Eur Heart J. 2014; 35: 1836-43.
Albadalejo G, García J, Lopez MF, Roldán V. Guía Sobre Los Nuevos Anticoagulantes Orales Sociedad Española de Hematología Y Hemoterapia / Sociedad Española De Trombosis Y Hemostasia.
Pautas E, Monti A, Breining A. Farmacología clínica comparada de los anticoagulantesorales: Avk Y Nuevos Anticoagulantes. Tratado de Medicina, Elsevier 2015; 19(1):1-5.
Vanden D, Peetermansb M, Vanasscheb T, Verhamme P, Vandermeulen E. Monitoring and reversal strategies for new oral anticoagulants. Expert Review Of Cardiovascular Therapy. 2015; 13:95-103.
Paramo JA. New Oral Anticoagulant Agents: The quandary of anticoagulation in the elderly. Medicina Clínica (Barc). 2013.
Pollack Ch, Jr. et al. Antidotes for bleeding caused by novel oral anticoagulants. Circulation. 2016; 133:18-19.
Weitz Ji, Eikelboom Jw, Samama Mm; American College of Chestphysicians. New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th Ed: American College Of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2): 120-151
Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology 2013; 145:105–112.
Freeman W, Aguilar I, Weitz J. Risk of intracerebral bleeding in patients treated with anticoagulants. Uptodate. 29 De Oct De 2013.
Vidal-Jordana I, Barroeta-Espar MP, Sáinz Pelayo J, Delgado-Mederos M, Martí-Fàbregas J. Hemorragias intracerebrales en pacientes anticoagulados, ¿qué hacemos después? Neurología. 2012; 27 (3):136—142.
Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007; 68:116—21
Diener Hc, Connolly Sj, Ezekowitz Md, Wallentin L, Reilly Pa, Yang S, et al, For The Re-Ly Study Group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the re-ly trial. Lancet Neurol. 2010; 9:1157-63.
Morgenstern LB, Hemphill JC, Anderson C, Becker K, Broderick JP, Connolly Jr ES. et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010; 41: p 2108—29.
García F, Dalmau B. La medicina actual ante los anticoagulantes de nueva generación. Med Clin (Barc). 2012; 138(10): p 438–440
San Miguel J, Sánchez-Guijo F. Fisiopatología De La Coagulación. En: San Miguel, Jesús F. Hematología: Manual Básico Razonado, Tercera Edición: España; Elsevier. 2009: 19; 199-212.
Marfil LJ. Fisiología de la Coagulación I. Función Plaquetaria. En: José Carlos Jaime Pérez, David Gómez Almaguer. Hematología la sangre y sus enfermedades. Segunda Edición. México, D.F. McGraw-Hill; 2009; 137-143.
Jonathan W, Yau Hwee Y, Subodh V. Endothelial cell control of thrombosis. Bmc Cardiovasc Disord. 2015; 15: 130.
Kenneth G, Mann Y, Kathleen E, Brummel Z. Normal coagulation. En: Jack L. Cronenwett, K. Wayne Johnston. Rutherford's Vascular Surgery. Eighth Edition. Philadelphia USA. Elsevier; 2014. P 528-548.
Van Hinsbergh Vw. Endothelium–Role in regulation of coagulation and inflammation. Semin Immunopathol. 2012; 34: 93–106.
Rachel C, Danczyk Y Timothy K. Liem. Hemostasis and thrombosis. En: Moore, Wesley. Vascular and Endovascular Surgery: A Comprehensive Review, Eighth Edition. Philadelphia USA. Elsevier; 2014. P 68-87.
Hall JE. Hemostasis and blood coagulation. En: Guyton and Hall Textbook of Medical Physiology, Thirteenth Edition. Jackson, Mississippi. Elsevier; 2016. P 483-494.
Gordon D.O, Lowey C. Bagot. Hemostasis and thrombosis. En: John W Baynes y Marek H Dominiczak. Medical Biochemistry Fourth Edition. Columbia, South Carolina Usa. Elsevier; 2014. 68-81.
Carvalhoy M, Loscalzo J. Normal Mechanisms of Vascular Hemostasis. En: Creager, Mark A. Vascular Medicine: A companion to braunwald's heart disease, second edition. Boston, massachusetts. Elsevier; 2013. P. 70-74.
Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: P. 2482-2494
Hajjar C, Esmon N, Marcus AJ, Muller A. Función Vascular En La Hemostasia. En: Marshall A. Lichtman, Keneth Kaushaky, Thomas J. Kipps, Josef P. Prchal. Marcel M. Levi. Williams Manual De Hematología. Octava Edición. Mcgraw-Hill; 2014. p. 1451-1470
Italiano J, Hartwig J. Megakaryocyte and Platelet Structure. In: Hoffman, Ronald. Hematology: Basic Principles and Practice, Sixth Edition. New York USA. Elsevier; 2013. 1797-1808
brams Ch, Plow E, Charles S. Molecular Basis for Platelet Function. In: Hoffman, Ronald. Hematology: Basic Principles and Practice, Sixth Edition. New York Usa. Elsevier; 2013. p. 1809-1820.
Parise L, Smyth S, Coller B. Morfología, bioquímica y función de las plaquetas. En: Marshall A. Lichtman, Keneth Kaushaky, Thomas J. Kipps, Josef P. Prchal. Marcel M. Levi. Williams Manual De Hematología. Octava Edición. Mcgraw-Hill; 2014. p. 1357-1408.
Patel-Hett S, Richardson Jl, Schulze H, et al: Visualization of microtubule growth in living platelets reveals a dynamic marginal band with multiple microtubules. Blood 2008; 111: p. 4605.
Italiano Je, Richardson Jl, Patelhett S, et al: Angiogenesis is regulated by a novelmechanism: proand antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008; 111: Pp. 1227
Bluteau D, Lordier L, Di Stefano A, et al: Regulation of megakaryocyte maturation and platelet formation. J Thromb Haemost 2009; 7: 227
Crawley J, Scully M, Zhang X. Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies. American Society of Hematology 2013.
Zhang X, Halvorsen K, Zhang CZ, Wong WP, Springer Ta. Mechanoenzymatic cleavage of the ultralarge vascular protein von willebrand factor. Science. 2009; 324 (5932):1330-1334.
Feys HB, Anderson PJ, Vanhoorelbeke K, Majerus Em, Sadlerje. Multi-Step Binding Of Adamts-13 to Von Willebrand Factor. J Thromb Haemost. 2009; 7(12):2088-2095.
Fuller Gl, Williams JA, Tomlinson Mg, et al. The C-type lectin receptors clec-2 and dectin-1, but not dc-sign, signal via a novel -dependent signaling cascade. J Biol Chem 2007; 282: 12397
Bertozzi C, Schmaier AA, Mericko P, et al. platelets regulate lymphatic vascular development through Clec-2-Slp-76 signaling. Blood 2010; 116: 661.
May F, Hagedorn I, Pleines I, et al. Clec-2 is an essential platelet-activating receptor in hemostasis and thrombosis. Blood 2009; 114: 3464
Wang Y, Litvinov RI, Chen X, et al. Loss of pipkigamma, unlike other pipki isoforms, impairs the integrity of the membrane cytoskeleton in murine megakaryocytes. J Clin Invest 2008; 118: 812.
Angiolillo Dj, Ferreiro Jl. Inhibición del receptor plaquetario p2 y 12 de adenosina difosfato plaquetario: efectos beneficiosos y limitaciones de las estrategias terapéuticas actuales y perspectivas futuras. Rev Esp Cardiol. 2010; 63: 60-76.
Davie EW, Ratnoff SI. Waterfall sequence for intrinsic blood clotting. Science. 1964; 145:1310-2.
Kriz N, Rinder C, Rinder H. Physiology of hemostasis: with relevance to current and future laboratory testing. Clinics in Laboratory Medicine, Vol. 29, Issue 2. p. 159–174.
Williams JC, Mackman N. Tissue factor in health and disease. Front Biosci (Elite Ed) 2012; 4: 358.
Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J. 2010; 31: 17-28
Erev E. Tubb, Mckenzie E. Trastornos de la hemostasia y la trombosis. En: Waldman, Scott A, Laurence J. Egan, Frcpi, Jean-Luc Elghozi, et al. Pharmacology and therapeutics: principles to practice, First Edition. Copyright © 2009 By Saunders, An Imprint Of Elsevier Inc. Chapter 63, 909-919.
Weitz Ji. Heparan Sulfate: Antithrombotic or not? J Clin Invest 2003; 111:952.
Giri TK, Ahn CW, Wu KK, et al. Heparin cofactor ii levels do not predict the development of coronary heart disease: the atherosclerosis risk in communities (Aric) Study. Arterioscler Thromb Vasc Biol 2005; 25: 2689
Broze Gj Jr, Girard Tj. Tissue factor pathway inhibitor: structure-function. Front Biosci. 2012: 17: 262–280.
Kasthuri RS, Glover Sl, Boles J, et al. Tissue factor and tissue factor pathway inhibitor as key regulators of global hemostasis: measurement of their levels in coagulation assays. Semin Thromb Hemost 2010; 36: 764.
Bode Mf, Mackman N. Protective and pathological roles of tissue factor in the heart. Hamostaseologie. 2014; 35.
Marx PF, Brondijk TH, Plug T, Romijn RA, Hemrikaw, Meijers JC, Huizinga Eg. Crystal structures of tafi elucidate the inactivation mechanism of activated tafi; a novel mechanism for enzyme autoregulation. Blood 2008; 112: 2803–9.
Rezaie Ar: regulation of the protein c anticoagulant and antiinflammatory pathways. Curr Med Chem 2010; 17: 2059.
isse J, Petersen HH, Larsen KS, Persson E, Esmon N, Esmon Ct, Teyton L, Petersen Lc, Ruf W. The endothelial protein c receptor supports tissue factor ternary coagulation initiation complex signaling through protease-activated receptors. J Biol Chem. 2011; 286: 5756–5767.
Konopatskaya O, Matthews SA, Harper MT, Gilio K, Cosemans JM, Williams CM, Navarro MN, Carter DA, Heemskerk JW, Leitges M, Cantrell D, Poole AW. Protein kinase c mediates platelet secretion and thrombus formation through protein kinase D2. 2011; 118: 416–424.
Versteeg HH, Heemskerk JW, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev. 2013; 93:327–58.
Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009; 7: P 4-13.
Castellino FJ, Ploplis VA. Structure and function of the plasminogen/ plasmin system. Thromb Haemost 2005; 93: 647–54.
Castellino FJ, Ploplis VA. Structure and function of the plasminogen/ plasmin system. Thromb Haemost 2005; 93: 647–54.
Adam SS, Key NS, Greenberg CS. Antígeno del Dímero D: Conceptos actuales y perspectivas de futuro. Sangre 2009; 113: 2878.
Righini M, Perrier A, De Moerloose P, et al: D Dimer for venous thromboembolism diagnosis: 20 years later. J Thromb Haemost 2008; 6: 1059.
Huber K. Plasminogen activator inhibitor type1 (part two): role for failure of thrombolytic therapy. Pai1 resistance as a potential benefit for new fibrinolytic agents. J Thromb Thrombolysis 2001; 11: 195.
Foley JH, Kim P, Nesheim ME. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis. J Biol Chem 2008; 283: 8863–7.
Bertina Rm, Van Tilburg NH, Haverkate F, Bouma BN, Von Dem-Borne PA, Meijers JC, Campbell W, Eaton D, Hendriks DF, Willemse Jl. Discovery of thrombin activatable fibrinolysis inhibitor (Tafi). J Thromb Haemost 2006; 4: 256–7.
Guimaraes AH, Laurens N, Weijers EM, Koolwijk P, Van Hinsbergh VW, Rijken DC. Tafi and pancreatic carboxypeptidase b modulate in vitro capillary tube formation by human microvascular endothelial cells. Arterioscler Thromb Vasc Biol 2007; 27:2157–62.
Foley JH, Kim P, Nesheim ME. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation offibrinolysis. J Biol Chem 2008; 283: 8863–7.
Christiansen VJ, Jackson KW, Lee KN, Mckee PA. The Effect of a Single nucleotide polymorphism in the alpha-2-antiplasmin human activity. Blood 2007; 109: 5286.
Law RH, Sofian T, Kanwt H, Hitchen CR, Langendorf CG, Buckle AM, Whisstock JC, Coughlin PB. X-Ray crystal structure of the fibrinolysis inhibitor alpha2-antiplasmin. Blood 2008; 111: 2049–52.
Law RH, Sofian T, Kanwt, Horvathaj, Hitchen CR, Langendorf CG, Buckle AM, Whisstock JC, Coughlin PB. X-ray crystal structure of the fibrinolysis inhibitor alpha2-antiplasmin. Blood 2008; 111: 2049–52.
Mann KG, Brummelziedins K, Orfeo T, et al: Models of blood coagulation. Blood Cells Mol Dis 2006; 36: 108.
Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev. 2003; 17(1): S1-S5.
Mann KG. Thrombin generation in hemorrhage control and vascular occlusion. Circulation 2011; 124: 225.
Monroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler. Thromb Vasc Biol. 2006; 26: 41–48.
Stavenuiter F, Dienava-Verdoold I, Boon-Spijker MG, Brinkman HJ, Meijer AB, Mertens K. Factor seven activating protease (Fsap): does it activate factor VII? J Thromb Haemost. 2012:10: 859–866.
Owens Iii AP, Mackman N. Role of tissue factor in atherothrombosis. Curr Atheroscler Rep. 2012; 14:394–401.
Ruf W, Disse J, Carneiro-Lobo TC, Yokota N, Schaffner F. Tissue factor andcell signalling in cancer progression and thrombosis. J Thromb Haemost. 2011; 9(1): 306–15.
. Versteeg HH, Heemskerk JJ, Levi M, Reitsma H. new fundamentals in hemostasis. Physiol Rev. 2013; 93: 327–358.
George M, Brenner Y, Craig W, Stevens Phd. Anticoagulant, antiplatelet, and fibrinolytic drugs. En: Pharmacology. Fourth Edition. Tulsa, Oklahoma. Elsevier. 2013: 156-167.
Barnes. W, Ageno J, Ansell S, kaatz T. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 13: 1154–1156.
Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A: Dabigatran Etexilate--A novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103:1116-1127.
Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G: Safety, Pharmacodynamics, and pharmacokinetics of single doses of bay 59- 7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78:412-421.
Prom R, Spinler Sa: The role of apixaban for venous and arterial thromboembolic Disease. Ann Pharmacother 2011; 45(10):1262-1283.
Ema. Ficha Técnica Rivaroxabán (Xarelto). Http://Www.Ema.Europa.Eu/Docs/Es_Es/Document_Library/Epar_Product_Inform ation/Human/000944/Wc500057108.Pdf. 2012.
Ficha Técnica Dabigatrán (Pradaxa). Http://Www.Ema.Europa.Eu/Docs/Es_Es/Document_Library/Epar__Product_Infor mation/Human/000829/Wc500041059.Pdf
You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2): 531S-75S.
Camm A, Gregory Y.H. Lip. Raffaele De Caterina. Savelieva. Dan Atar. Stefan H. Hohnloser, et al. Actualización detallada de las guías de la ESC para el manejo de la fibrilación auricular de 2012. Rev Esp Cardiol. 2013; 66(1):54.e1-e24.
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. For the RE-LY steering committee and investigators. Dabigatran Versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139-51.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. For the ROCKET AF investigators. Rivaroxaban Versus Warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-91
Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. For The AVERROES steering committee and investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364: 806.
Granger CB, Alexander JH, Mcmurray JJ, Lopes RD, Hylek EM, Hanna M, et al, For the ARISTOTLE committees and investigators. Apixaban Versus Warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-92.
Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt D, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366:9-19.
Eriksson BI. Dahl OE. Huo MH. Kurth AA. Hantel S. Hermansson K, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011; 105(4): 721-9.
Lassen R, Raskob GE, Gallus A, Pineo G, Chen D. et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010: 375: p807–815.
Eriksson B, Borris L, Friedman R, Haas S, Huisman M, Kakkar A, et al. Rivaroxaban versus Enoxaparin for thromboprophylaxis after hip arthroplasty. RECORD1. N Engl J Med 2008; 358: 2765-2775.
. Lassen M, Borris L, Lieberman J, Rosencher N, Bandel T. Rivaroxaban versus Enoxaparin for thromboprophylaxis after total knee arthroplasty record 2. N Engl J Med 2008; 358:2776-2786.
. Lassen M, Borris L, Lieberman J, Rosencher N, Bandel T. Rivaroxaban versus Enoxaparin for thromboprophylaxis after total knee arthroplasty record 2. N Engl J Med 2008; 358:2776-2786.
. Lassen M, Borris L, Lieberman J, Rosencher N, Bandel T. Rivaroxaban versus Enoxaparin for thromboprophylaxis after total knee arthroplasty record 2. N Engl J Med 2008; 358:2776-2786.
Lassen M, Ageno W, Borris L, Lieberman J, Rosencher N, Rivaroxaban T. versus Enoxaparin for thromboprophylaxis after total knee arthroplasty. RECORD 3.N Engl J Med 2008; 358:2776-2786.
Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomised trial. Lancet. 2009; 373(9676): 1673-80.
Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361: 2342-52.
Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS. et al. Einstein investigators. Oral Rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363: 2499-510.
Lozano FS. Nuevos anticoagulantes orales en el tratamiento de la trombosis venosa profunda. Angiología. 2012; 64(5):212---217.
Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS. et al. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. N Engl J Med 2012; 366:1287-129.
Agnelli G, Harry R, Bulle D, Cohen A. Curto M, Gallus A. Oral Apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369:799- 808.
Giuseppe Lippi J, Favaloro J. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?. Clin Chem Lab Med 2015; 53(2): 185–197.
Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamic of oral dabigatran etexilate. Clin Pharmacol 2010; 49:259-268.
Kitchen S, McCraw A, Echenagucia M. Preparación y calibración de un pool de plasma normal (PPN). Diagnóstico de la hemofilia y otros trastornos de la coagulación. Manual de Laboratorio Segunda edición Publicado por la Federación Mundial de Hemofilia (FMH). 2010.
Douxfils J, Mullier F, Robert S, et al: Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107: pp. 985-997.
Hawes EM, Funk-D Adcock, Gosselin R, Jeanneret C. Cook AM, Taylor JM. et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost. 2013; 11(8):1493-502.
Cushman M, Lim W, Zakai NA. Clinical practice guide on anticoagulant dosing and management of anticoagulant-associated bleeding complications in adults. The American Society of Hematology; 2011[http://222.hemataology.org/Practice/Guidelines/2934.aspx. Pblished 2011. Accessed 11Feb2015].
Jones S.D., Eaddy N.S., Chan G.T. Dabigatran: laboratory monitoring. Pathology 2012; 44: pp. 578-580
Tripodi A, Chantarangkul V, Guinet C, Samama MM. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban- treated patients: results of an in vitro study. J Thromb Haemost 2011; 9: 226–8. 12.
Zafar M, Vorchheimer D, Gaztanaga J, Velez M, Yadegar D, Moreno P, et al. Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost. 2007 Oct; 98(4):883-8
Weitz J, Connolly S, Patel I, Salazar D, Rohatagi S, Mendell J. et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010 Sep; 104(3):633-41.
Cuker A, Siegal D, Crowther M, García D. Laboratory measurement of the anticoagulant activity of the non–vitamin K oral anticoagulants. Journal of the American College of Cardiology. 2014; 6 4: 1128–1139.
Chai-Adisaksopha C, Hillis T, Isayama W, Lim A, Iorio M, Crowthe. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. Journal of Thrombosis and Haemostasis. 2015; 13: pages 2012–2020.
Temboury F, Buforn M, Cabrera-Bueno F. New oral anticoagulants: Management bleeding complications. Cardiocore. 2014; 49(3):102–104
Neena S, Abrahama, Castillo D. Novel anticoagulants: bleeding risk and management strategies. Curr Opin Gastroenterol 2013; 29:676–683.
Marano G, Vaglio S, Pupella S, Liumbruno G, Franchini M. How we treat bleeding associated with direct oral anticoagulants. Blood Transfus. 2016; 0180- 15.
Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, et al. Hemostatic therapy in experimental intracerebralhemorrhage associated with the direct thrombin inhibitor dabi-gatran. Stroke. 2011; 42: 3594.
Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatranby prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011; 124:1573.
Van Ryn J, Ruehl D, Priepke H, Hauel N, Wienen W. Reversibility of the anticoagulant effect of high doses of the directthrombin inhibitor dabigatran, by recombinant factor VIIa oractivated prothrombin complex concentrate. Haematologica.2008; 93(s1):148. Abs.O370
Pollack C, Reilly P, Eikelboom J, Glund S, Verhamme P, Bernstein R, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 373: 511-52.
Siegal D, Curnutte J, Connolly S, Lu G, Conley P, Wiens B, et al. Andexanet Alfa for the Reversal of Factor X Inhibitor Activity. N Engl J Med 2015; 373:2413- 24.
Niessner A, Tamargo J, MoraisJ, Koller J, Wassmann S, Elkjær Husted S, et al. Reversal strategies for non-vitamin k antagonist oral anticoagulants: a critical 108 appraisal of available evidence and recommendations for clinical management—a joint position paper of the european society of cardiology working group on cardiovascular pharmacotherapy and european society of cardiology working group on thrombosis. European Heart Journal Advance Access published December 24, 2015.
Siega D, Cuker A. Reversal of novel oral anticoagulants in patients with major bleeding. Journal of Thrombosis and Thrombolysis April 2013, Volume 35, Issue 3, pp 391-398.
dc.relation.references.SPA.fl_str_mv Arribalzaga K, Asenjo S, Cesar J, Llamas Y, Oña F. Rodríguez AM, et al. Guía de uso de dabigatrán etexilato (pradaxa®) en la prevención del ictus y embolismo sistémico en los pacientes con fibrilación auricular no valvular y otros factores de riesgo. Asociación Madrileña De Hematología Y Hemoterapia (AMHH). 2012
Gómez A, Lecumberri R. Antidotes for the new oral anticoagulants: Reality and expectations. Medicina Clínica (Barc). 2016.
López A, Macayaa C. Plaqueta: Fisiología de la activación y la inhibición. Rev Esp Cardiol. 2013; 13: 2-7.
Alvarado I. Fisiología de la coagulación: nuevos conceptos aplicados al cuidado perioperatorio. Univ. Méd. 2013; 54: 338-352.
Mateo J, Santamaria A, Fontcuberta J. Fisiología y exploración de la hemostasia. En: J. Sans-Sabrafen C. Besses Raebel J.L. Vives Corrons. Hematología Clínica. Quinta Edición. Madrid España. Elsevier. 2007; 659-681.
Gómez OA, Melgarejo E. Anticoagulación. Sociedad Colombiana De Cardiología y Cirugía Cardiovascular. Junta Directiva 2003-2005.
Quintero-González JA, cincuenta años de uso clínico de la warfarina. Invest Clin. 2010; 51(2): 269 - 287.
Laurence L. Brunton, Bruce A. Chabner, Björn C. Knollmann, Goodman G. Las bases farmacológicas de la terapéuticas 12ed. México: Interamericana Mcgraw-Hill Interamericana Editores 2012: 30:857-866
Tadros R, Shakib S. Warfarin--Indications, risks and drug interactions. aust famphysician. [En Línea] 2010 Jul [Consultado Set 2012]; 39(7): 476-9. Disponible En: Http://Www.Racgp.Org.Au/Afp/201007/201007tadros_Warfain.Pdf
Flórez J, Sedano M.C. Farmacología de la hemostasia, la coagulación y la fibrinólisis. En: Florez J, Armijo J, Mediavilla A. Farmacología Humana. 3a Ed. Barcelona: Masson S.A.; 1997. Cap. 46: 794-803.
García F, Dalmau B. La medicina actual ante los anticoagulantes de nueva generación. Medicina Clínica. Med Clin (Barc). 2012; 138(10):438–440
Yurgakya J, Rodríguez F. Warfarina: uso contemporáneo. Revista Med. 2009: 17 (1): 107-115.
Mateo J. Nuevos anticoagulantes orales y su papel en la práctica clínica. Revista Española Cardiología Supl. 2013; 13(C):33-41.
Escolar E, García J, López MF, Roldán V. Guía sobre los nuevos anticoagulantes orales. Sociedad española de hematología y hemoterapia / sociedad española de trombosis y hemostasia. 2012.
Ema. Ficha Técnica Apixabán (Eliquis).Http://Www.Ema.Europa.Eu/Docs/En_Gb/Document_Library/Epar_Produc t_Information/Human/002148/Wc500107728.Pdf 2012.
Altman R. Los Nuevos Anticoagulantes Orales (Nacos). ¿Pongr qué debemos controlar su actividad anticoagulante? Rev Fed Arg Cardiol. 2014; 43(2): 60
Arribalzaga K, Asenjo S, Pérez C, Llamas P, Oña F, Rodriguez AM, et al. Guía de uso de rivaroxabán (Xarelto®) en la prevención del ictus y embolismo sistémico en los pacientes conm fibrilación auricular no valvular y otros factores de riesgo. Asociación Madrileña de Hematología y Hemoterapia (AMHH). Diciembre 2012.
Ortiz G, Ariza F, Trujillo G, Bejaranob A, Gutiérrez JM, Gálvese K, et al. Manejo del sangrado y la coagulación en la prácticaclínica. Evaluación de la 107 evidencia y recomendacionesmediante estrategia GRADE. Primera reuniónde expertos. Acta Colomb Cuid Intensivo. 2016.
Labrador J, González-Porras R. ¿Qué hacer ante una complicación hemorrágica en pacientes tratados con nuevos anticoagulantes orales? Angiología. 2015; 67(2):118-124.
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rights.license.*.fl_str_mv Atribución-NoComercial-SinDerivadas 2.5 Colombia
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/2.5/co/
Atribución-NoComercial-SinDerivadas 2.5 Colombia
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv PDF
dc.format.mimetype.none.fl_str_mv application/pdf
dc.coverage.spatial.spa.fl_str_mv Barranquilla
institution Universidad Libre
bitstream.url.fl_str_mv http://repository.unilibre.edu.co/bitstream/10901/10236/1/MONOGRAFIA%20DE%20MONITORIZACION%20Y%20REVERSION%20DE%20DOACs.pdf
http://repository.unilibre.edu.co/bitstream/10901/10236/2/license.txt
http://repository.unilibre.edu.co/bitstream/10901/10236/3/MONOGRAFIA%20DE%20MONITORIZACION%20Y%20REVERSION%20DE%20DOACs.pdf.jpg
bitstream.checksum.fl_str_mv c38e7ccef878305220945bf01dcf905d
8a4605be74aa9ea9d79846c1fba20a33
e0b82d4399f224c5c9a051e6c1d13807
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Unilibre
repository.mail.fl_str_mv repositorio@unilibrebog.edu.co
_version_ 1814090399662211072
spelling González Aguirre, IreneIglesias Acosta, JesúsCarrillo Navarro, María ClaudiaGuerrero García, Augusto SantiagoBarranquilla2017-07-26T19:02:54Z2017-07-26T19:02:54Z2016https://hdl.handle.net/10901/10236instname:Universidad Librereponame:Repositorio Institucional Universidad LibreLa tromboembolia representa una importante causa de morbimortalidad, siendo la anticoagulación el pilar del tratamiento. Los anticoagulantes orales directos, constituyen una opción que supera algunos de los inconvenientes con warfarina, como la monitorización rutinaria. No obstante con su inclusión en la práctica clínica, surgieron otras limitaciones: la dificultad para su medición cuando se requiere, debido a la poca disponibilidad y estandarización de pruebas hemostáticas; y la falta de antídotos para reversión, frente a hemorrágicas severas. Sin embargo recientemente fue aprobado idarucizumab, un anticuerpo monoclonal que neutraliza al dabigatrán, no disponible en Colombia. Se concluye que estos fármacos, son una opción atractiva, que requieren el desarrollo de pruebas diagnósticas y agentes de reversión específicos accesibles. Se realizó una búsqueda en bases de datos como Pubmed, Clinical Key, Embase, Evidence- Based MEDICINE, con las palabras clave dabigatrán, rivaroxabán, apixabán, monitorización, sangrado. Se incluyó literatura en idioma inglés y español entre 1998-2016.Thromboembolism is a major cause of morbidity and mortality, with anticoagulation being the mainstay of treatment. The direct oral anticoagulants are an option to overcome some of the drawbacks of warfarin, such as routine monitoring. Nevertheless, new constraints have emerged by their inclusion in clinical practice: the difficulty in measuring, due to the limited availability and standardization of hemostatic tests; and the lack of antidotes for reversal, to deal with severe bleeding. However, idarucizumab was recently approved, it’s a monoclonal antibody that neutralizes dabigatran, but is not available in Colombia. We concluded that these drugs are an attractive option, which require the development of diagnostic tests and available specific reversal agents. We made the research on databases such as Pubmed, Clinical Key, Embase, Evidence-Based Medicine, with keywords dabigatran, rivaroxaban, apixaban, monitoring, bleeding. We include the literature in English and Spanish language between 1998 and 2016.PDFapplication/pdfspahttp://creativecommons.org/licenses/by-nc-nd/2.5/co/Atribución-NoComercial-SinDerivadas 2.5 Colombiainfo:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2AnticoagulantesTromboemboliaTromboemboliaTromboemboliaMedicamentosDabigatranRivaroxabanApixabanMonitoringBleedingHEMORRAGIADABIGATRÁNRIVAROXABÁNAPIXABÁNDabigatránRivaroxabánApixabánMonitorizaciónSangradoAnticoagulantes orales directos: monitorización y reversión, dos grandes dificultadesTesis de Especializacióninfo:eu-repo/semantics/acceptedVersionhttp://purl.org/coar/resource_type/c_7a1finfo:eu-repo/semantics/bachelorThesisMozaffarian D, Roger Vl, Benjamin BJ, Berry JD, Blaha MJ, et. al. Heart disease and stroke. Statistics—2014 Update A Report From The American Heart Association. Circulation. 2014; (129): 399-410.Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna Wp, et al. Secular trends in incidence of atrial fibrillation in olmsted county, minnesota, 1980 To 2000, And Implications On The Projections For Future Prevalence. Circulation. 2006; 114:119–25Ezekowitz MD, Falk RH. The increasing need for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Mayo Clin Proc. 2004: 79:904–13.Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet.1998; 352:1167–71.Hart R, Diener H, Shelagh B, Coutts MD,Donald Easton J, Granger C, O'donnell M, et al. Embolic strokes of undetermined source: The case for a new clinical construc. The Lancet Neurology. 2014; (13): 429-438.Kernan WN, Chair MD, Ovbiagele B, Chair V, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack a guideline for healthcare professionals from the American heart association/american stroke association. Stroke. 2014. (45):1-77.Bhupathiraju SN, Hu FB, et al. Epidemiology of obesity and diabetes and their cardiovascular complications. Circ Res. 2016; 118(11):1723-35.Marín F, Sánchez P, Cortina JM, García JA, Jiménez D, Lecumberri R, et al. Comentarios a la guía de práctica clínica de la ESC 2014 sobre el diagnóstico y tratamiento de la embolia pulmonar aguda Rev Esp Crdaridoilo. 2015; 68 (1): 10- 16.Paul D, Stein Md Y Fadi Matta Md. Epidemiology and Incidence: The scope of the problem and risk factors for development of venous thromboembolism. Crit Care Clin Volumen 2011; 907–932Stein PD, Matta F. Acute pulmonary embolism. Curr Prob Cardiol 2010; 35:314–76.Ubaldini J, Chertcoff J, Sampó E, Casey M, Ceresetto J, Boughen R. Consenso de enfermedad tromboembólica- consenso argentino sac. Revista Argentina De Cardiología. 2009; 77(5): 411-428.Dennis R, Rojas MX, Molina A, Roa J, Granados M, Londoño A, et al. Clinical course and survival in pulmonary embolism results of the Colombian multicentric registry (emepco). Acta Médica Colombiana. 2008 Volumen (33 N° 3): 111-116.January C, Wann S, Alpert J, Field M, Calkins H, Murray K, et al. Aha/Acc/Hrs guideline for the management of patients withatrial fibrillationa report of the american college of cardiology/american heart association task force on practice guidelines and the heart rhythm society. Circulation. 2014; (129:000–000)Hart R, Lesly A. Pearce, et al. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146(12):857-867.Fernández M, Rueda Y, Villa V, Belmonte S, Stoyanova A. Análisis del perfil sociosanitario del paciente anticoagulado en España. Federación Española De Asociaciones De Anticoagulados. 2013.Brummel K, Kenneth G. Molecular basis of blood coagulation. En: Hoffman, Ronald. Hematology: Basic Principles and Practice, Sixth Edition. New York USA. Elsevier. 2013; 1821-1841.Kang-Ling W, Pao-Hsien C, Cheng-Han L, Pei-Ying P, Pao-Yen L, Kou-Gi S, et al. Management Of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis. Act Cardiol Sin. 2016; 32:122.Aguilar M, Hart R, Pearce L. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patientswith non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007; (6): 186- 198Fontana P, Robert-Ebadi H, Bounameaux H, Boehlen F, Righini M. Direct oral anticoagulants: A Guide For Daily Practice. Medical Intelligence. 2016; 146:W14286.Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors of thrombin and factor Xa: A recommendation from the subcommittee on control of anticoagulation of the scientific and standardization committee of the international society on thrombosis and haemostasis. J Thromb Haemost 2013; 11: 756–60.Fontana P, Goldhaber S, Bounameaux H. Anticoagulantes orales directas en el tratamiento y la prevención a largo plazo del tromboembolismo venoso. Eur Heart J. 2014; 35: 1836-43.Albadalejo G, García J, Lopez MF, Roldán V. Guía Sobre Los Nuevos Anticoagulantes Orales Sociedad Española de Hematología Y Hemoterapia / Sociedad Española De Trombosis Y Hemostasia.Pautas E, Monti A, Breining A. Farmacología clínica comparada de los anticoagulantesorales: Avk Y Nuevos Anticoagulantes. Tratado de Medicina, Elsevier 2015; 19(1):1-5.Vanden D, Peetermansb M, Vanasscheb T, Verhamme P, Vandermeulen E. Monitoring and reversal strategies for new oral anticoagulants. Expert Review Of Cardiovascular Therapy. 2015; 13:95-103.Paramo JA. New Oral Anticoagulant Agents: The quandary of anticoagulation in the elderly. Medicina Clínica (Barc). 2013.Pollack Ch, Jr. et al. Antidotes for bleeding caused by novel oral anticoagulants. Circulation. 2016; 133:18-19.Weitz Ji, Eikelboom Jw, Samama Mm; American College of Chestphysicians. New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th Ed: American College Of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2): 120-151Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology 2013; 145:105–112.Freeman W, Aguilar I, Weitz J. Risk of intracerebral bleeding in patients treated with anticoagulants. Uptodate. 29 De Oct De 2013.Vidal-Jordana I, Barroeta-Espar MP, Sáinz Pelayo J, Delgado-Mederos M, Martí-Fàbregas J. Hemorragias intracerebrales en pacientes anticoagulados, ¿qué hacemos después? Neurología. 2012; 27 (3):136—142.Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007; 68:116—21Diener Hc, Connolly Sj, Ezekowitz Md, Wallentin L, Reilly Pa, Yang S, et al, For The Re-Ly Study Group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the re-ly trial. Lancet Neurol. 2010; 9:1157-63.Morgenstern LB, Hemphill JC, Anderson C, Becker K, Broderick JP, Connolly Jr ES. et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010; 41: p 2108—29.García F, Dalmau B. La medicina actual ante los anticoagulantes de nueva generación. Med Clin (Barc). 2012; 138(10): p 438–440San Miguel J, Sánchez-Guijo F. Fisiopatología De La Coagulación. En: San Miguel, Jesús F. Hematología: Manual Básico Razonado, Tercera Edición: España; Elsevier. 2009: 19; 199-212.Marfil LJ. Fisiología de la Coagulación I. Función Plaquetaria. En: José Carlos Jaime Pérez, David Gómez Almaguer. Hematología la sangre y sus enfermedades. Segunda Edición. México, D.F. McGraw-Hill; 2009; 137-143.Jonathan W, Yau Hwee Y, Subodh V. Endothelial cell control of thrombosis. Bmc Cardiovasc Disord. 2015; 15: 130.Kenneth G, Mann Y, Kathleen E, Brummel Z. Normal coagulation. En: Jack L. Cronenwett, K. Wayne Johnston. Rutherford's Vascular Surgery. Eighth Edition. Philadelphia USA. Elsevier; 2014. P 528-548.Van Hinsbergh Vw. Endothelium–Role in regulation of coagulation and inflammation. Semin Immunopathol. 2012; 34: 93–106.Rachel C, Danczyk Y Timothy K. Liem. Hemostasis and thrombosis. En: Moore, Wesley. Vascular and Endovascular Surgery: A Comprehensive Review, Eighth Edition. Philadelphia USA. Elsevier; 2014. P 68-87.Hall JE. Hemostasis and blood coagulation. En: Guyton and Hall Textbook of Medical Physiology, Thirteenth Edition. Jackson, Mississippi. Elsevier; 2016. P 483-494.Gordon D.O, Lowey C. Bagot. Hemostasis and thrombosis. En: John W Baynes y Marek H Dominiczak. Medical Biochemistry Fourth Edition. Columbia, South Carolina Usa. Elsevier; 2014. 68-81.Carvalhoy M, Loscalzo J. Normal Mechanisms of Vascular Hemostasis. En: Creager, Mark A. Vascular Medicine: A companion to braunwald's heart disease, second edition. Boston, massachusetts. Elsevier; 2013. P. 70-74.Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: P. 2482-2494Hajjar C, Esmon N, Marcus AJ, Muller A. Función Vascular En La Hemostasia. En: Marshall A. Lichtman, Keneth Kaushaky, Thomas J. Kipps, Josef P. Prchal. Marcel M. Levi. Williams Manual De Hematología. Octava Edición. Mcgraw-Hill; 2014. p. 1451-1470Italiano J, Hartwig J. Megakaryocyte and Platelet Structure. In: Hoffman, Ronald. Hematology: Basic Principles and Practice, Sixth Edition. New York USA. Elsevier; 2013. 1797-1808brams Ch, Plow E, Charles S. Molecular Basis for Platelet Function. In: Hoffman, Ronald. Hematology: Basic Principles and Practice, Sixth Edition. New York Usa. Elsevier; 2013. p. 1809-1820.Parise L, Smyth S, Coller B. Morfología, bioquímica y función de las plaquetas. En: Marshall A. Lichtman, Keneth Kaushaky, Thomas J. Kipps, Josef P. Prchal. Marcel M. Levi. Williams Manual De Hematología. Octava Edición. Mcgraw-Hill; 2014. p. 1357-1408.Patel-Hett S, Richardson Jl, Schulze H, et al: Visualization of microtubule growth in living platelets reveals a dynamic marginal band with multiple microtubules. Blood 2008; 111: p. 4605.Italiano Je, Richardson Jl, Patelhett S, et al: Angiogenesis is regulated by a novelmechanism: proand antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008; 111: Pp. 1227Bluteau D, Lordier L, Di Stefano A, et al: Regulation of megakaryocyte maturation and platelet formation. J Thromb Haemost 2009; 7: 227Crawley J, Scully M, Zhang X. Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies. American Society of Hematology 2013.Zhang X, Halvorsen K, Zhang CZ, Wong WP, Springer Ta. Mechanoenzymatic cleavage of the ultralarge vascular protein von willebrand factor. Science. 2009; 324 (5932):1330-1334.Feys HB, Anderson PJ, Vanhoorelbeke K, Majerus Em, Sadlerje. Multi-Step Binding Of Adamts-13 to Von Willebrand Factor. J Thromb Haemost. 2009; 7(12):2088-2095.Fuller Gl, Williams JA, Tomlinson Mg, et al. The C-type lectin receptors clec-2 and dectin-1, but not dc-sign, signal via a novel -dependent signaling cascade. J Biol Chem 2007; 282: 12397Bertozzi C, Schmaier AA, Mericko P, et al. platelets regulate lymphatic vascular development through Clec-2-Slp-76 signaling. Blood 2010; 116: 661.May F, Hagedorn I, Pleines I, et al. Clec-2 is an essential platelet-activating receptor in hemostasis and thrombosis. Blood 2009; 114: 3464Wang Y, Litvinov RI, Chen X, et al. Loss of pipkigamma, unlike other pipki isoforms, impairs the integrity of the membrane cytoskeleton in murine megakaryocytes. J Clin Invest 2008; 118: 812.Angiolillo Dj, Ferreiro Jl. Inhibición del receptor plaquetario p2 y 12 de adenosina difosfato plaquetario: efectos beneficiosos y limitaciones de las estrategias terapéuticas actuales y perspectivas futuras. Rev Esp Cardiol. 2010; 63: 60-76.Davie EW, Ratnoff SI. Waterfall sequence for intrinsic blood clotting. Science. 1964; 145:1310-2.Kriz N, Rinder C, Rinder H. Physiology of hemostasis: with relevance to current and future laboratory testing. Clinics in Laboratory Medicine, Vol. 29, Issue 2. p. 159–174.Williams JC, Mackman N. Tissue factor in health and disease. Front Biosci (Elite Ed) 2012; 4: 358.Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J. 2010; 31: 17-28Erev E. Tubb, Mckenzie E. Trastornos de la hemostasia y la trombosis. En: Waldman, Scott A, Laurence J. Egan, Frcpi, Jean-Luc Elghozi, et al. Pharmacology and therapeutics: principles to practice, First Edition. Copyright © 2009 By Saunders, An Imprint Of Elsevier Inc. Chapter 63, 909-919.Weitz Ji. Heparan Sulfate: Antithrombotic or not? J Clin Invest 2003; 111:952.Giri TK, Ahn CW, Wu KK, et al. Heparin cofactor ii levels do not predict the development of coronary heart disease: the atherosclerosis risk in communities (Aric) Study. Arterioscler Thromb Vasc Biol 2005; 25: 2689Broze Gj Jr, Girard Tj. Tissue factor pathway inhibitor: structure-function. Front Biosci. 2012: 17: 262–280.Kasthuri RS, Glover Sl, Boles J, et al. Tissue factor and tissue factor pathway inhibitor as key regulators of global hemostasis: measurement of their levels in coagulation assays. Semin Thromb Hemost 2010; 36: 764.Bode Mf, Mackman N. Protective and pathological roles of tissue factor in the heart. Hamostaseologie. 2014; 35.Marx PF, Brondijk TH, Plug T, Romijn RA, Hemrikaw, Meijers JC, Huizinga Eg. Crystal structures of tafi elucidate the inactivation mechanism of activated tafi; a novel mechanism for enzyme autoregulation. Blood 2008; 112: 2803–9.Rezaie Ar: regulation of the protein c anticoagulant and antiinflammatory pathways. Curr Med Chem 2010; 17: 2059.isse J, Petersen HH, Larsen KS, Persson E, Esmon N, Esmon Ct, Teyton L, Petersen Lc, Ruf W. The endothelial protein c receptor supports tissue factor ternary coagulation initiation complex signaling through protease-activated receptors. J Biol Chem. 2011; 286: 5756–5767.Konopatskaya O, Matthews SA, Harper MT, Gilio K, Cosemans JM, Williams CM, Navarro MN, Carter DA, Heemskerk JW, Leitges M, Cantrell D, Poole AW. Protein kinase c mediates platelet secretion and thrombus formation through protein kinase D2. 2011; 118: 416–424.Versteeg HH, Heemskerk JW, Levi M, Reitsma PH. New fundamentals in hemostasis. Physiol Rev. 2013; 93:327–58.Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009; 7: P 4-13.Castellino FJ, Ploplis VA. Structure and function of the plasminogen/ plasmin system. Thromb Haemost 2005; 93: 647–54.Castellino FJ, Ploplis VA. Structure and function of the plasminogen/ plasmin system. Thromb Haemost 2005; 93: 647–54.Adam SS, Key NS, Greenberg CS. Antígeno del Dímero D: Conceptos actuales y perspectivas de futuro. Sangre 2009; 113: 2878.Righini M, Perrier A, De Moerloose P, et al: D Dimer for venous thromboembolism diagnosis: 20 years later. J Thromb Haemost 2008; 6: 1059.Huber K. Plasminogen activator inhibitor type1 (part two): role for failure of thrombolytic therapy. Pai1 resistance as a potential benefit for new fibrinolytic agents. J Thromb Thrombolysis 2001; 11: 195.Foley JH, Kim P, Nesheim ME. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis. J Biol Chem 2008; 283: 8863–7.Bertina Rm, Van Tilburg NH, Haverkate F, Bouma BN, Von Dem-Borne PA, Meijers JC, Campbell W, Eaton D, Hendriks DF, Willemse Jl. Discovery of thrombin activatable fibrinolysis inhibitor (Tafi). J Thromb Haemost 2006; 4: 256–7.Guimaraes AH, Laurens N, Weijers EM, Koolwijk P, Van Hinsbergh VW, Rijken DC. Tafi and pancreatic carboxypeptidase b modulate in vitro capillary tube formation by human microvascular endothelial cells. Arterioscler Thromb Vasc Biol 2007; 27:2157–62.Foley JH, Kim P, Nesheim ME. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation offibrinolysis. J Biol Chem 2008; 283: 8863–7.Christiansen VJ, Jackson KW, Lee KN, Mckee PA. The Effect of a Single nucleotide polymorphism in the alpha-2-antiplasmin human activity. Blood 2007; 109: 5286.Law RH, Sofian T, Kanwt H, Hitchen CR, Langendorf CG, Buckle AM, Whisstock JC, Coughlin PB. X-Ray crystal structure of the fibrinolysis inhibitor alpha2-antiplasmin. Blood 2008; 111: 2049–52.Law RH, Sofian T, Kanwt, Horvathaj, Hitchen CR, Langendorf CG, Buckle AM, Whisstock JC, Coughlin PB. X-ray crystal structure of the fibrinolysis inhibitor alpha2-antiplasmin. Blood 2008; 111: 2049–52.Mann KG, Brummelziedins K, Orfeo T, et al: Models of blood coagulation. Blood Cells Mol Dis 2006; 36: 108.Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev. 2003; 17(1): S1-S5.Mann KG. Thrombin generation in hemorrhage control and vascular occlusion. Circulation 2011; 124: 225.Monroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler. Thromb Vasc Biol. 2006; 26: 41–48.Stavenuiter F, Dienava-Verdoold I, Boon-Spijker MG, Brinkman HJ, Meijer AB, Mertens K. Factor seven activating protease (Fsap): does it activate factor VII? J Thromb Haemost. 2012:10: 859–866.Owens Iii AP, Mackman N. Role of tissue factor in atherothrombosis. Curr Atheroscler Rep. 2012; 14:394–401.Ruf W, Disse J, Carneiro-Lobo TC, Yokota N, Schaffner F. Tissue factor andcell signalling in cancer progression and thrombosis. J Thromb Haemost. 2011; 9(1): 306–15.. Versteeg HH, Heemskerk JJ, Levi M, Reitsma H. new fundamentals in hemostasis. Physiol Rev. 2013; 93: 327–358.George M, Brenner Y, Craig W, Stevens Phd. Anticoagulant, antiplatelet, and fibrinolytic drugs. En: Pharmacology. Fourth Edition. Tulsa, Oklahoma. Elsevier. 2013: 156-167.Barnes. W, Ageno J, Ansell S, kaatz T. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 13: 1154–1156.Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A: Dabigatran Etexilate--A novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103:1116-1127.Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G: Safety, Pharmacodynamics, and pharmacokinetics of single doses of bay 59- 7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78:412-421.Prom R, Spinler Sa: The role of apixaban for venous and arterial thromboembolic Disease. Ann Pharmacother 2011; 45(10):1262-1283.Ema. Ficha Técnica Rivaroxabán (Xarelto). Http://Www.Ema.Europa.Eu/Docs/Es_Es/Document_Library/Epar_Product_Inform ation/Human/000944/Wc500057108.Pdf. 2012.Ficha Técnica Dabigatrán (Pradaxa). Http://Www.Ema.Europa.Eu/Docs/Es_Es/Document_Library/Epar__Product_Infor mation/Human/000829/Wc500041059.PdfYou JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2): 531S-75S.Camm A, Gregory Y.H. Lip. Raffaele De Caterina. Savelieva. Dan Atar. Stefan H. Hohnloser, et al. Actualización detallada de las guías de la ESC para el manejo de la fibrilación auricular de 2012. Rev Esp Cardiol. 2013; 66(1):54.e1-e24.Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. For the RE-LY steering committee and investigators. Dabigatran Versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139-51.Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. For the ROCKET AF investigators. Rivaroxaban Versus Warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-91Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. For The AVERROES steering committee and investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364: 806.Granger CB, Alexander JH, Mcmurray JJ, Lopes RD, Hylek EM, Hanna M, et al, For the ARISTOTLE committees and investigators. Apixaban Versus Warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-92.Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt D, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366:9-19.Eriksson BI. Dahl OE. Huo MH. Kurth AA. Hantel S. Hermansson K, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). A randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011; 105(4): 721-9.Lassen R, Raskob GE, Gallus A, Pineo G, Chen D. et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010: 375: p807–815.Eriksson B, Borris L, Friedman R, Haas S, Huisman M, Kakkar A, et al. Rivaroxaban versus Enoxaparin for thromboprophylaxis after hip arthroplasty. RECORD1. N Engl J Med 2008; 358: 2765-2775.. Lassen M, Borris L, Lieberman J, Rosencher N, Bandel T. Rivaroxaban versus Enoxaparin for thromboprophylaxis after total knee arthroplasty record 2. N Engl J Med 2008; 358:2776-2786.. Lassen M, Borris L, Lieberman J, Rosencher N, Bandel T. Rivaroxaban versus Enoxaparin for thromboprophylaxis after total knee arthroplasty record 2. N Engl J Med 2008; 358:2776-2786.. Lassen M, Borris L, Lieberman J, Rosencher N, Bandel T. Rivaroxaban versus Enoxaparin for thromboprophylaxis after total knee arthroplasty record 2. N Engl J Med 2008; 358:2776-2786.Lassen M, Ageno W, Borris L, Lieberman J, Rosencher N, Rivaroxaban T. versus Enoxaparin for thromboprophylaxis after total knee arthroplasty. RECORD 3.N Engl J Med 2008; 358:2776-2786.Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): a randomised trial. Lancet. 2009; 373(9676): 1673-80.Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361: 2342-52.Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS. et al. Einstein investigators. Oral Rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363: 2499-510.Lozano FS. Nuevos anticoagulantes orales en el tratamiento de la trombosis venosa profunda. Angiología. 2012; 64(5):212---217.Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS. et al. Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. N Engl J Med 2012; 366:1287-129.Agnelli G, Harry R, Bulle D, Cohen A. Curto M, Gallus A. Oral Apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369:799- 808.Giuseppe Lippi J, Favaloro J. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus?. Clin Chem Lab Med 2015; 53(2): 185–197.Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamic of oral dabigatran etexilate. Clin Pharmacol 2010; 49:259-268.Kitchen S, McCraw A, Echenagucia M. Preparación y calibración de un pool de plasma normal (PPN). Diagnóstico de la hemofilia y otros trastornos de la coagulación. Manual de Laboratorio Segunda edición Publicado por la Federación Mundial de Hemofilia (FMH). 2010.Douxfils J, Mullier F, Robert S, et al: Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107: pp. 985-997.Hawes EM, Funk-D Adcock, Gosselin R, Jeanneret C. Cook AM, Taylor JM. et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost. 2013; 11(8):1493-502.Cushman M, Lim W, Zakai NA. Clinical practice guide on anticoagulant dosing and management of anticoagulant-associated bleeding complications in adults. The American Society of Hematology; 2011[http://222.hemataology.org/Practice/Guidelines/2934.aspx. Pblished 2011. Accessed 11Feb2015].Jones S.D., Eaddy N.S., Chan G.T. Dabigatran: laboratory monitoring. Pathology 2012; 44: pp. 578-580Tripodi A, Chantarangkul V, Guinet C, Samama MM. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban- treated patients: results of an in vitro study. J Thromb Haemost 2011; 9: 226–8. 12.Zafar M, Vorchheimer D, Gaztanaga J, Velez M, Yadegar D, Moreno P, et al. Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost. 2007 Oct; 98(4):883-8Weitz J, Connolly S, Patel I, Salazar D, Rohatagi S, Mendell J. et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010 Sep; 104(3):633-41.Cuker A, Siegal D, Crowther M, García D. Laboratory measurement of the anticoagulant activity of the non–vitamin K oral anticoagulants. Journal of the American College of Cardiology. 2014; 6 4: 1128–1139.Chai-Adisaksopha C, Hillis T, Isayama W, Lim A, Iorio M, Crowthe. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. Journal of Thrombosis and Haemostasis. 2015; 13: pages 2012–2020.Temboury F, Buforn M, Cabrera-Bueno F. New oral anticoagulants: Management bleeding complications. Cardiocore. 2014; 49(3):102–104Neena S, Abrahama, Castillo D. Novel anticoagulants: bleeding risk and management strategies. Curr Opin Gastroenterol 2013; 29:676–683.Marano G, Vaglio S, Pupella S, Liumbruno G, Franchini M. How we treat bleeding associated with direct oral anticoagulants. Blood Transfus. 2016; 0180- 15.Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, et al. Hemostatic therapy in experimental intracerebralhemorrhage associated with the direct thrombin inhibitor dabi-gatran. Stroke. 2011; 42: 3594.Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatranby prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011; 124:1573.Van Ryn J, Ruehl D, Priepke H, Hauel N, Wienen W. Reversibility of the anticoagulant effect of high doses of the directthrombin inhibitor dabigatran, by recombinant factor VIIa oractivated prothrombin complex concentrate. Haematologica.2008; 93(s1):148. Abs.O370Pollack C, Reilly P, Eikelboom J, Glund S, Verhamme P, Bernstein R, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 373: 511-52.Siegal D, Curnutte J, Connolly S, Lu G, Conley P, Wiens B, et al. Andexanet Alfa for the Reversal of Factor X Inhibitor Activity. N Engl J Med 2015; 373:2413- 24.Niessner A, Tamargo J, MoraisJ, Koller J, Wassmann S, Elkjær Husted S, et al. Reversal strategies for non-vitamin k antagonist oral anticoagulants: a critical 108 appraisal of available evidence and recommendations for clinical management—a joint position paper of the european society of cardiology working group on cardiovascular pharmacotherapy and european society of cardiology working group on thrombosis. European Heart Journal Advance Access published December 24, 2015.Siega D, Cuker A. Reversal of novel oral anticoagulants in patients with major bleeding. Journal of Thrombosis and Thrombolysis April 2013, Volume 35, Issue 3, pp 391-398.Arribalzaga K, Asenjo S, Cesar J, Llamas Y, Oña F. Rodríguez AM, et al. Guía de uso de dabigatrán etexilato (pradaxa®) en la prevención del ictus y embolismo sistémico en los pacientes con fibrilación auricular no valvular y otros factores de riesgo. Asociación Madrileña De Hematología Y Hemoterapia (AMHH). 2012Gómez A, Lecumberri R. Antidotes for the new oral anticoagulants: Reality and expectations. Medicina Clínica (Barc). 2016.López A, Macayaa C. Plaqueta: Fisiología de la activación y la inhibición. Rev Esp Cardiol. 2013; 13: 2-7.Alvarado I. Fisiología de la coagulación: nuevos conceptos aplicados al cuidado perioperatorio. Univ. Méd. 2013; 54: 338-352.Mateo J, Santamaria A, Fontcuberta J. Fisiología y exploración de la hemostasia. En: J. Sans-Sabrafen C. Besses Raebel J.L. Vives Corrons. Hematología Clínica. Quinta Edición. Madrid España. Elsevier. 2007; 659-681.Gómez OA, Melgarejo E. Anticoagulación. Sociedad Colombiana De Cardiología y Cirugía Cardiovascular. Junta Directiva 2003-2005.Quintero-González JA, cincuenta años de uso clínico de la warfarina. Invest Clin. 2010; 51(2): 269 - 287.Laurence L. Brunton, Bruce A. Chabner, Björn C. Knollmann, Goodman G. Las bases farmacológicas de la terapéuticas 12ed. México: Interamericana Mcgraw-Hill Interamericana Editores 2012: 30:857-866Tadros R, Shakib S. Warfarin--Indications, risks and drug interactions. aust famphysician. [En Línea] 2010 Jul [Consultado Set 2012]; 39(7): 476-9. Disponible En: Http://Www.Racgp.Org.Au/Afp/201007/201007tadros_Warfain.PdfFlórez J, Sedano M.C. Farmacología de la hemostasia, la coagulación y la fibrinólisis. En: Florez J, Armijo J, Mediavilla A. Farmacología Humana. 3a Ed. Barcelona: Masson S.A.; 1997. Cap. 46: 794-803.García F, Dalmau B. La medicina actual ante los anticoagulantes de nueva generación. Medicina Clínica. Med Clin (Barc). 2012; 138(10):438–440Yurgakya J, Rodríguez F. Warfarina: uso contemporáneo. Revista Med. 2009: 17 (1): 107-115.Mateo J. Nuevos anticoagulantes orales y su papel en la práctica clínica. Revista Española Cardiología Supl. 2013; 13(C):33-41.Escolar E, García J, López MF, Roldán V. Guía sobre los nuevos anticoagulantes orales. Sociedad española de hematología y hemoterapia / sociedad española de trombosis y hemostasia. 2012.Ema. Ficha Técnica Apixabán (Eliquis).Http://Www.Ema.Europa.Eu/Docs/En_Gb/Document_Library/Epar_Produc t_Information/Human/002148/Wc500107728.Pdf 2012.Altman R. Los Nuevos Anticoagulantes Orales (Nacos). ¿Pongr qué debemos controlar su actividad anticoagulante? Rev Fed Arg Cardiol. 2014; 43(2): 60Arribalzaga K, Asenjo S, Pérez C, Llamas P, Oña F, Rodriguez AM, et al. Guía de uso de rivaroxabán (Xarelto®) en la prevención del ictus y embolismo sistémico en los pacientes conm fibrilación auricular no valvular y otros factores de riesgo. Asociación Madrileña de Hematología y Hemoterapia (AMHH). Diciembre 2012.Ortiz G, Ariza F, Trujillo G, Bejaranob A, Gutiérrez JM, Gálvese K, et al. Manejo del sangrado y la coagulación en la prácticaclínica. Evaluación de la 107 evidencia y recomendacionesmediante estrategia GRADE. Primera reuniónde expertos. Acta Colomb Cuid Intensivo. 2016.Labrador J, González-Porras R. ¿Qué hacer ante una complicación hemorrágica en pacientes tratados con nuevos anticoagulantes orales? Angiología. 2015; 67(2):118-124.ORIGINALMONOGRAFIA DE MONITORIZACION Y REVERSION DE DOACs.pdfMONOGRAFIA DE MONITORIZACION Y REVERSION DE DOACs.pdfTrabajo de Gradoapplication/pdf2415383http://repository.unilibre.edu.co/bitstream/10901/10236/1/MONOGRAFIA%20DE%20MONITORIZACION%20Y%20REVERSION%20DE%20DOACs.pdfc38e7ccef878305220945bf01dcf905dMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748http://repository.unilibre.edu.co/bitstream/10901/10236/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52THUMBNAILMONOGRAFIA DE MONITORIZACION Y REVERSION DE DOACs.pdf.jpgMONOGRAFIA DE MONITORIZACION Y REVERSION DE DOACs.pdf.jpgIM Thumbnailimage/jpeg4657http://repository.unilibre.edu.co/bitstream/10901/10236/3/MONOGRAFIA%20DE%20MONITORIZACION%20Y%20REVERSION%20DE%20DOACs.pdf.jpge0b82d4399f224c5c9a051e6c1d13807MD5310901/10236oai:repository.unilibre.edu.co:10901/102362022-10-11 12:08:26.656Repositorio Institucional Unilibrerepositorio@unilibrebog.edu.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

Publicaciones similares